Cargando…
Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
Antibody deficiency is the most frequently encountered primary immunodeficiency disease (PIDD) and patients who lack the ability to make functional immunoglobulin require life-long replacement therapy to prevent serious bacterial infections. Human serum immunoglobulin manufactured from pools of dona...
Autores principales: | Skoda-Smith, Suzanne, Torgerson, Troy R, Ochs, Hans D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817783/ https://www.ncbi.nlm.nih.gov/pubmed/20169031 |
Ejemplares similares
-
Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
por: Shabaninejad, Hosein, et al.
Publicado: (2017) -
Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014) -
476 Severe Autoimmunity with Polyarticular Joint Disease Requiring Anti-TNF Therapy and T+B-NK+ Immunodeficiency in a Family with Small Stature and Intermediate Radiation Sensitivity
por: Torgerson, Troy, et al.
Publicado: (2012) -
Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
por: Mallick, Rajiv, et al.
Publicado: (2018) -
Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)